Bridging Anticoagulation: The BRIDGE Study on Atrial Fibrillation and Warfarin Therapy

The document discussed bridging anticoagulation, which involves using a short-acting blood thinner to reduce blood clot risks when warfarin therapy is paused for surgery, but this may increase bleeding risks post-surgery. It introduced the BRIDGE study, a randomized trial aiming to assess the necessity of bridging anticoagulation in over 3600 patients with atrial fibrillation stopping warfarin for elective procedures, across the United States, Canada, and Brazil. The study was designed to address the lack of high-quality clinical data on who should receive bridging anticoagulation, highlighting the global impact of its potential findings.